Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15738696 | 0.80 | CFTR (0.57) | SMN1; SMN2MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL16389665 | 0.80 | AGBL2 (0.54) | SMN1; SMN2MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL16666657 | 0.78 | KMT2A (0.50) | SMN1; SMN2MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL15922616 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL9928605 | 0.78 | MAPT (0.47) | SMN1; SMN2MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL30134211 | 0.78 | MAPT (0.47) | SMN1; SMN2MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL707954 | 0.77 | MAPT (0.46) | SMN1; SMN2MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL15862919 | 0.77 | KMT2A (0.49) | SMN1; SMN2MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL707320 | 0.77 | ALDH1A1 (0.63) | SMN1; SMN2MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL30056948 | 0.77 | CASP1 (0.52) | SMN1; SMN2MAPTALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | SMN1; SMN2 2486/4885MAPT 3950/4885KDM4E 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.